Open Label Phase 2 Pilot Trial of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)
Latest Information Update: 24 Jan 2022
At a glance
- Drugs Tofacitinib (Primary)
- Indications Discoid lupus erythematosus; Systemic lupus erythematosus
- Focus Therapeutic Use
- 06 Jan 2022 Status changed from recruiting to discontinued.
- 21 Aug 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 21 Aug 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.